Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Taro Pharmaceutical Industries Ltd. (TARO) (TARO)

65.61   1.55 (2.42%) 04-09 15:03
Open: 64.57 Pre. Close: 64.06
High: 66.5 Low: 64.77
Volume: 35,692 Market Cap: 2529M
Taro Pharmaceutical Industries Ltd is a science-based pharmaceutical company. It develops, manufacture and market Rx and OTC (over-the-counter) pharmaceutical products primarily in the United States, Canada and Israel.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 64.283 - 64.538 64.538 - 64.758
Low: 61.254 - 61.565 61.565 - 61.832
Close: 63.514 - 64.03 64.03 - 64.474

Technical analysis

as of: 2020-04-09 10:05:55 AM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 79.76     One year: 93.16
Support: Support1: 60.74    Support2: 56.07
Resistance: Resistance1: 68.29    Resistance2: 79.76
Pivot: 61.75
Moving Average: MA(5): 63.53     MA(20): 62.20
MA(100): 79.02     MA(250): 83.18
MACD: MACD(12,26): -1.31     Signal(9): -2.20
Stochastic oscillator: %K(14,3): 75.21     %D(3): 65.89
RSI: RSI(14): 50.99
52-week: High: 109.42  Low: 56.07  Change(%): -38.4
Average Vol(K): 3-Month: 5230  10-Days: 3623

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
TARO has closed below upper band by 5.2%. Bollinger Bands are 40.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to TARO's normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

2020-03-18
Crescita Reports Q4 and Fiscal 2019 Results
Record Annual Revenue of $22.3M Record Adjusted EBITDA of $7.0M up from $1.5M LAVAL, QC , March 18, 2020 /CNW/ - Crescita Therapeutics Inc. (TSX: CTX ) (GREY: CRRTF ) ("Crescita" or the "Company"), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development ("R&D") and manufacturing capabilities, today reported its financial results for the fourth quarter ("Q4-F2019") and fiscal year ended December 31, 2019 ("F2019"). All amounts are in thousands of Canadian dollars except for share and per share amounts, unless otherwise noted. Year-over-year Financial Highlights F2019 vs. F2018 Record revenue of $22,337 , an increase of $5,709 or 34.3%; Recognized $5,459 in up-front payments and guaranteed future minimum royalties related to the out-licensing agreement with Cantabria Labs (see below); Recognized $2,645 (US$2,000) in sales milestones from Taro related to the achievement of the final cumulative targets for the U.S. sales of Pliaglis®; Recognized a development milestone of $988 (US$750) from Taro related to the approval of an enhanced formulation of Pliaglis by the FDA (defined below); Operating expenses of $17,369 , an increase of $704 or 4.2%; Record Adjusted EBITDA 1 of $6,984 , an improvement of $5,533 versus $1,451 ; Repaid the Knight Loan in full in the amount of $3,570 (see below); Generated $4,249 in cash before repayment of the Knight Loan, resulting in closing cash position of $9,268 compared to $8,598 at the end of 2018.

2020-03-03
The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 2) Forty Seven Inc (NASDAQ: FTSV )( announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD )) IGM Biosciences Inc (NASDAQ: IGMS ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Karyopharm Therapeutics Inc (NASDAQ: KPTI )(announced positive late-stage results for selinexor) Passage Bio Inc (NASDAQ: PASG )(IPOed Friday) Syneos Health Inc (NASDAQ: SYNH ) Trillium Therapeutics Inc (NASDAQ: TRIL )(moved in sympathy with Forty Seven, as it has a similar drug in the pipeline for solid tumor) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 2) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akorn, Inc. (NASDAQ: AKRX ) ANI Pharmaceuticals Inc (NASDAQ: ANIP )(moved lower despite FDA nod for a generic version of Teva Pharmaceutical Industries Ltd's (NYSE: TEVA ) Alzheimer's related dementia drug) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) (reacted to its fourth-quarter results) Evolus Inc (NASDAQ: EOLS ) EXACT Sciences Corporation (NASDAQ: EXAS ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Imv Inc (NASDAQ: IMV ) Neurometrix Inc (NASDAQ: NURO ) Portola Pharmaceuticals Inc (NASDAQ: PTLA ) Precigen Inc (NASDAQ: PGEN ) Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) TherapeuticsMD Inc (NASDAQ: TXMD ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Viking Therapeutics Inc (NASDAQ: VKTX ) Related Link: How The COVID-19 Outbreak Is Benefiting Biotech Investors Stocks In Focus GenMark Starts Shipping COVID-19 Test Kits GenMark said it has begun shipping ePlex Research Use Only, or RUO, test kits to detect COVID-19 virus.

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  New York Stock Exchange
Sector:  Healthcare
Industry:  Drug Manufacturers - Specialty Generic
Shares Out. (M) 38.54
Shares Float (M) 8.82
% Held by Insiders 77.10
% Held by Institutions 11.97
Shares Short (K) 220
Shares Short P. Month (K) 154

Stock Financials

EPS 6.440
Book Value (p.s.) 53.580
PEG Ratio
Profit Margin 38.24
Operating Margin 40.77
Return on Assets (ttm) 7.6
Return on Equity (ttm) 12.7
Qtrly Rev. Growth -16.3
Gross Profit (p.s.) 11.565
Sales Per Share 16.859
EBITDA (p.s.) 7.417
Qtrly Earnings Growth -27.60
Operating Cash Flow (M) 280.59
Levered Free Cash Flow (M) 153.41

Stock Valuations

P/E 10.06
P/E Growth Ratio 0.01
P/BV 1.21
P/S
P/CF 8.90

Dividends & Splits

Dividend
Dividend Yield
Dividend Pay Date 2018-12-27
Ex-Dividend Date 2018-12-09
Forward Dividend
Last Split Date
Last Split Ratio 2
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2019 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.